Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Travoprost
Drug ID BADD_D02265
Description Travoprost ophthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure [FDA Label]. It is a synthetic prostaglandin F2alpha analog [FDA Label]. Having been a well-received therapeutic agent with demonstrated efficacy and safety, travoprost is currently approved by the US FDA as a first-line treatment for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypotension [L5155]. Furthermore, this approval also solidifies the medication as the first and only prostaglandin analog approved by the FDA for first-line treatment of glaucoma patients that does not contain the preservative benzalkonium chloride [L5155]. Moreover, travoprost is also currently approved in the EU for the decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma [L5146, L5152].
Indications and Usage Ophthalmic solution used for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are intolerant of other intraocular pressure lowering medications or insufficiently responsive (failed to achieve target IOP determined after multiple measurements over time) to another intraocular pressure lowering medication.
Marketing Status Prescription; Discontinued
ATC Code S01EE04
DrugBank ID DB00287
KEGG ID D01964
MeSH ID D000069557
PubChem ID 5282226
TTD Drug ID D09CZA
NDC Product Code 54893-0020; 40016-006; 0078-0946; 82231-114; 45542-1162; 38779-3063; 64181-0028; 63629-8839; 65035-131; 65129-1207; 61556-040; 0781-6185; 24002-0022; 68245-0003; 63190-0350; 60505-0593; 63629-8840; 55359-540
Synonyms Travoprost | Travatan Z | Z, Travatan | Travatan | (((1R)-(1alpha(Z),2beta(1E,3R*),3alpha,5alpha))-7-(3,5-dihydroxy-2-(3-hydroxy-4-(3-trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-5-heptenoic acid, 1-methylethyl ester | AL-6221 | AL 6221 | AL6221
Chemical Information
Molecular Formula C26H35F3O6
CAS Registry Number 157283-68-6
SMILES CC(C)OC(=O)CCCC=CCC1C(CC(C1C=CC(COC2=CC=CC(=C2)C(F)(F)F)O)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Conjunctivitis allergic10.01.04.002; 06.04.01.003--Not Available
Constipation07.02.02.001--
Corneal epithelium defect06.06.03.012--Not Available
Corneal erosion06.06.03.003--Not Available
Corneal pigmentation06.06.03.013--Not Available
Cough22.02.03.001--
Death08.04.01.001--
Depression19.15.01.001--
Dermatitis23.03.04.002--Not Available
Dermatitis atopic10.01.04.004; 23.03.04.016--Not Available
Dermatitis contact23.03.04.004; 12.03.01.040; 10.01.01.003--Not Available
Diabetes mellitus14.06.01.001; 05.06.01.0010.001187%Not Available
Diarrhoea07.02.01.001--
Diplopia17.17.01.005; 06.02.06.0020.001187%Not Available
Discomfort08.01.08.003--Not Available
Dizziness17.02.05.003; 02.01.02.004; 24.06.02.0070.002770%
Drug hypersensitivity10.01.01.001--Not Available
Dry eye06.08.02.0010.002770%
Dry mouth07.06.01.002--
Dysgeusia17.02.07.003; 07.14.03.001--
Dyspepsia07.01.02.001--
Dysphonia17.02.08.004; 22.02.05.005; 19.19.03.002--
Dyspnoea02.01.03.002; 22.02.01.004--
Dysuria20.02.02.002--
Ear disorder04.03.01.001--Not Available
Ectropion23.07.05.001; 06.06.04.001--Not Available
Eczema eyelids06.04.04.012; 23.03.04.027--Not Available
Endophthalmitis11.01.06.003; 06.04.05.009--
Erythema23.03.06.001--Not Available
Erythema of eyelid23.03.06.006; 06.04.04.0030.000791%Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 8 Pages